Cowen's Conviction on Jazz Pharmaceuticals (JAZZ) 'Growing Stronger', Buy on Weakness
Tweet Send to a Friend
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $200.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ), saying their conviction ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
